Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
| ▸ | MC3R | P41968 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.54 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.54 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5719031 | 0.83 | ADORA2B (0.54) | P2RX7ADORA2BSMN1; SMN2RXFP1ADORA2A | |
| SCHEMBL8598384 | 0.81 | ADORA2B (0.51) | P2RX7ADORA2BSMN1; SMN2RXFP1ADORA2A | |
| SCHEMBL5718827 | 0.81 | L3MBTL1 (0.58) | ADORA2BSMN1; SMN2RXFP1ADORA2APIK3CD | |
| SCHEMBL515911 | 0.79 | ADORA2B (0.61) | P2RX7ADORA2BSMN1; SMN2RXFP1ADORA2A | |
| SCHEMBL5719123 | 0.78 | MAPK1 (0.56) | SMN1; SMN2POLBLMNAALDH1A1MAPK1 | |
| SCHEMBL458792 | 0.77 | HTR7 (0.63) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL29375465 | 0.77 | HTR7 (0.63) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL684356 | 0.77 | HTR7 (0.58) | ADORA2BSMN1; SMN2RXFP1LMNAALDH1A1 | |
| SCHEMBL2955104 | 0.77 | P2RX7 (0.43) | P2RX7ADORA2BSMN1; SMN2RXFP1ADORA2A | |
| SCHEMBL5719350 | 0.77 | ADORA2B (0.43) | P2RX7ADORA2BSMN1; SMN2RXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074798-B2 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1338595-B1 | Xanthine derivatives as DPP-IV inhibitors | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | P2RX7 110/4885ADORA2B 269/4885SMN1; SMN2 3959/4885 |
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | P2RX7 1045/4885ADORA2B 979/4885SMN1; SMN2 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.